Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microwave zapper could replace lung surgery for some cancers

NCT ID NCT06869122

Disease control Sponsor: Creo Medical Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new device that uses microwave energy to heat and destroy lung tumors. 18 people with lung cancer who are already scheduled for surgery will receive this ablation first. The goal is to see if the device is safe and can effectively kill the tumor, which might one day allow patients to avoid surgery altogether.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Microwave ablation device (MicroBlate Flex)
What this could lead to
If successful, this technique could offer a less invasive option for treating lung tumors, potentially avoiding the need for surgery in future patients.
What could go wrong
This is a very early, small study (18 people) focused on safety and technical success, not on long-term outcomes. The ablation is done before planned surgery, so it's not yet a standalone treatment.
Why investors are watching

Creo Medical is testing its MicroBlate Flex device, which uses microwave energy to destroy lung tumors through a bronchoscope. The trial enrolls 18 people who will have the ablation before their scheduled surgery, letting researchers compare the device's effect against the removed tissue. For a micro-cap company, this small study is a key step toward showing the device works in the lung, a new area beyond its existing uses.

If it works: A positive safety and performance result could support Creo Medical's case for regulatory approval and broader adoption of the device. It may also open the door to treating lung cancer patients without surgery, which would expand the company's market.

If it fails: The trial could fail to show the device is safe or effective, or it could face delays in enrollment or completion. Clinical trials often fail, and for a small company, a negative result could set back its plans and hurt its credibility.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

General population going through lung cancer screening at investigative site.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who: 1. Have signed informed consent. 2. Subject is willing and able to comply with all aspects of the treatment and evaluation schedule. 3. Are ≥ 18 years old. 4. Have lung lesion(s)/nodule(s) which are histopathological confirmed as cancer. 5. Have soft tissue lung lesion(s): * ≤ 20 mm in the largest dimension of the pulmonary window 6. Are candidates for surgical resection as determined by a multi-disciplinary team (MDT) or tumour board. 7. \> 10 mm of tumour-free lung parenchyma between target tumour and pleura or fissure. 8. Subject is willing and able to comply with the study protocol requirements. 9. Are assigned an ASA (American Society of Anaesthesiologists) score of ≤ 3 or the patient is deemed fit for general anaesthesia. Exclusion Criteria: Patients who: 1. Have target nodule(s) within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord, and phrenic \& laryngeal nerves). 2. Are pregnant or breast feeding, as determined by standard site practices. 3. Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study. 4. Have a physical or psychological condition that would impair study participation or jeopardise the safety or welfare of the subject. 5. Have an expected survival less than 12 months. 6. Have an implantable device, including pacemakers or other electronic implants. 7. Have known pulmonary hypertension (PASP \[pulmonary artery systolic pressure\] \>50mmHg). 8. Subject had a prior pneumonectomy. 9. Diagnosis of Small Cell Lung Cancer. 10. Subject had a therapeutic intervention (e.g., SBRT) within same lobe as the target lesion. 11. Subjects currently undergoing or underwent chemotherapy, systemic immunosuppressive treatment, or radiotherapy within 3 months of planned Study procedure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Europeo di Oncologia (IEO), Via Ripamonti 435

    NOT_YET_RECRUITING

    Milan, 20141, Italy

  • Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street

    RECRUITING

    London, UK, SW3 6NP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.